The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial.
John P. Neoptolemos
Honoraria - Kael GemVax
Research Funding - Kael GemVax
William Greenhalf
No relevant relationships to disclose
Trevor F. Cox
No relevant relationships to disclose
Eithne Costello
No relevant relationships to disclose
Victoria Shaw
No relevant relationships to disclose
Juan W. Valle
Honoraria - Lilly
Fareeda Y. Coxon
No relevant relationships to disclose
Jonathan Wadsley
No relevant relationships to disclose
David Propper
No relevant relationships to disclose
Paul J. Ross
Honoraria - Celgene
Srinivasan Madhusudan
No relevant relationships to disclose
Tom Roques
No relevant relationships to disclose
David Cunningham
Research Funding - Amgen; AstraZeneca; Celgene; Merck Serono; Novartis; Roche; Sanofi
Martin McKinlay Eatock
Consultant or Advisory Role - Celgene
Tim Iveson
No relevant relationships to disclose
Kinnari Patel
No relevant relationships to disclose
Angel Garcia-Alonso
No relevant relationships to disclose
Gemma Nanson
No relevant relationships to disclose
Gary Middleton
No relevant relationships to disclose